COMMUNIQUÉS West-GlobeNewswire

Worlds First Online Direct Messaging Therapy Service for Muslims
02/07/2019
TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- TherapyLine.org launched in April of 2019 in Canada as the world’s first anonymous online direct messaging Therapy Platform geared towards Muslims. Living in Michigan, Founder [...]
Transactions in relation to share buyback program
02/07/2019
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 1, 2019, in accordance with article 5 of Regulation (EU) no. 596/2014 of April 16, 2014 on [...]
BBS share issue completed 215 new shareholders in Sweden
02/07/2019
BBS – Bioactive Bone Substitutes Oyj (“BBS or “Company”), an innovator in orthobiologics, today announced the final outcome of the share issue to increase the number of shareholders in Sweden (“Offering”), for which the [...]
ESPERITE (N.V) WITH CRYOSAVE ANNOUNCES THE RELEASE OF TWO CORD BLOOD STEM CELLS SAMPLES FOR TREATMENTS AND THEREFORE CONFIRMS THE IMPORTANCE OF STEM CELLS IN THE FIELD OF REGENERATIVE MEDICINE.
02/07/2019
ESPERITE (N.V) WITH CRYOSAVE ANNOUNCES THE RELEASE OF TWO CORD BLOOD STEM CELLS SAMPLES FOR TREATMENTS AND THEREFORE CONFIRMS THE IMPORTANCE OF STEM CELLS IN THE FIELD OF REGENERATIVE MEDICINE. Amsterdam, The [...]
CellaVision AB presents the second quarter for 2019 on July 16 at 11:00 CET
02/07/2019
The information was submitted to the public on July 2, 2019 at 8:20 CET CellaVision AB (publ) will publish the interim report for the second quarter on July 16, 2019 at 8:20 CET. The report will be available at www. [...]
Curetis To Attend Key Conferences in the Third Quarter of 2019
02/07/2019
Amsterdam, the Netherlands, and Holzgerlingen, Germany, July 2, 2019, 08:00 am CET - Curetis N.V. (the " Company " and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic [...]
SV Health Investors announces the appointment of Jonathan Behr, PhD as Partner in the Dementia Discovery Fund
02/07/2019
SV Health Investors announces the appointment of Jonathan Behr, PhD as Partner in the Dementia Discovery Fund Former founding managing director of JDRF T1D Fund joins DDF leadership team London, 2 July 2019 - The [...]
Oasmia appoints new CMO
02/07/2019
Nina Heldring, PhD, has today been appointed as acting CMO of Oasmia Pharmaceutical AB. Nina Heldring has 20 years of experience with pre-clinical and clinical medical research from renowned academic institutes and the [...]
Oasmia appoints Scientific Advisory Board
02/07/2019
Oasmia today announces the formation of its Scientific Advisory Board with three key appointments: Professor Rolf Lewensohn, MD, PhD, Hans Grönlund, PhD and Ola Winqvist, MD, PhD. The scientific advisory board will work [...]
Aino Health AB (publ): Aino Health signs cooperation agreement with Aava Occupational Health
02/07/2019
Aino Health and Aava Finland, one of Finland’s largest Occupational Health providers have signed a cooperation agreement where Aava will sell Aino HealthManager and connected implementations services. This cooperation [...]
Nicox signs agreement for NCX 4251 in China with Ocumension Therapeutics for up to €12 million in milestones plus royalties
02/07/2019
Press Release Nicox signs agreement for NCX 4251 in China with Ocumension Therapeutics for up to €12 million in milestones plus royalties Upfront payment of €2 million and potential future milestones of €10 million [...]
Nicox : signature d’un accord sur NCX 4251 avec Ocumension Therapeutics pour la Chine. Paiements d’étape pouvant atteindre 12 millions d’euros plus redevances
02/07/2019
Communiqué de presse Nicox : signature d’un accord sur NCX 4251 avec Ocumension Therapeutics pour la Chine. Paiements d’étape pouvant atteindre 12 millions d’euros plus redevances Paiement initial de 2 millions d’euros [...]
GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR
02/07/2019
Mechelen, Belgium; 2 July 2019; 07.00 CET; regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) today announced that at a recent pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration [...]
Bone Therapeutics SA: Information on the total number of voting rights and shares
02/07/2019
Regulated information Gosselies, Belgium, 2 July 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological [...]
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
02/07/2019
Information réglementée Gosselies, Belgique, le 2 juillet 2019, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de thérapies [...]
Cancer Research UK forms partnership with SV Health Investors in life sciences investment fund to accelerate development of cancer medicines
02/07/2019
PRESS RELEASE FOR DISTRIBUTION TO FINANCIAL JOURNALISTS Cancer Research UK forms partnership with SV Health Investors in life sciences investment fund to accelerate development of cancer medicines Strategic partnership [...]
Telix Pharmaceuticals and PI Medical Sign Distribution Agreement for the Netherlands
02/07/2019
MELBOURNE, Australia and RAAMSDONKSVEER, Netherlands, July 02, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the [...]
HTG Presents at the 11th Annual Edition of the Worldwide Innovative Networking (WIN) Symposium
01/07/2019
TUCSON, Ariz., July 01, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that it presented its [...]
Adaptive Biotechnologies Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
01/07/2019
SEATTLE, July 01, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune [...]

Pages